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Enhanced arginase (ARG) activity has been identified as a factor that reduces nitric oxide
production and impairs endothelial function in vascular pathologies. Using a gene dele-
tion model, we investigated involvement of arginase isoforms arginase 1 and 2 (ARG1
and ARG2) in hypertension and endothelial dysfunction in a mineralocorticoid-salt mouse
model. Hypertension was induced in wild type (WT), partial ARG1+/− knockout (KO),
and complete ARG2−/− KO mice by uninephrectomy and deoxycorticosterone acetate
(DOCA)-salt treatment for 6-weeks. (Control uninephrectomized mice drank tap water.)
After 2 weeks of DOCA-salt treatment, systolic blood pressure (SBP) was increased by
∼15 mmHg in all mouse genotypes. SBP continued to rise in DOCA-salt WT and ARG2−/−
mice to ∼130 mmHg at 5–6 weeks, whereas in ARG1+/− mice SBP waned toward control
levels by 6 weeks (109±4 vs. 101±3 mmHg, respectively). DOCA-salt treatment in WT
mice increased vascular ARG activity (aorta by 1.5-fold; mesenteric artery (MA) by 2.6-fold
and protein levels of ARG1 (aorta: 1.49-fold and MA: 1.73-fold) vs. WT Sham tissues. ARG2
protein increased in WT-DOCA MA (by 2.15-fold) but not in aorta compared to those of
WT Sham tissues. Maximum endothelium-dependent vasorelaxation to acetylcholine was
significantly reduced in DOCA-salt WT mice and largely or partially maintained in DOCA
ARG1+/− and ARG2−/− mice vs. their Sham controls. DOCA-salt augmented contractile
responses to phenylephrine in aorta of all mouse genotypes. Additionally, treatment of
aorta or MA from WT-DOCA mice with arginase inhibitor (100µM) improved endothelium-
mediated vasorelaxation. DOCA-salt-induced coronary perivascular fibrosis (increased by
2.1-fold) inWT was prevented in ARG1+/− and reduced in ARG2−/−mice. In summary, ARG
is involved in murine DOCA-salt-induced impairment of vascular function and hypertension
and may represent a novel target for antihypertensive therapy.
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INTRODUCTION
Arterial hypertension remains a major risk factor for cardiovascu-
lar disease morbidity. It affects about 26% of the adult population
(1). Despite current drugs being effective in many patients, a
large number of uncontrolled patients are still very evident today.
Hypertension is associated with physiological and biochemical
changes in the vessel wall, characterized by turbulent blood flow,
fluid shear stress, vascular remodeling, and endothelial dysfunc-
tion. During the past few years, many studies have demonstrated
that nitric oxide (NO) pathway is a major regulator of cardio-
vascular functions, and evidence has accumulated that enhanced
arginase (ARG) activity is involved in the pathogenesis of several
cardiovascular disorders, including hypertension (2, 3).
Arginase is a crucial manganese metalloenzyme in the hepatic
urea cycle that catalyzes conversion of l-arginine to ornithine and
urea. It exists in two isoforms, arginase 1 (ARG1) and arginase 2
(ARG2). Each is encoded by a separate gene and found in vascular
tissues, endothelial, and smooth muscle cells, but their distribution
is vessel- and species-dependent (4–6). In the endothelium ARG
activity appears as a critical regulator for NO production by com-
peting with endothelial NO synthase (eNOS) for l-arginine (7).
Related studies have shown that increased ARG activity/expression
is involved in many vascular pathologies including atherosclero-
sis (6, 8), aging (9), diabetes (10, 11), and hypertension (12–14).
Blood pressure is mainly regulated by the tone of resistance ves-
sels. Increased ARG activity and diminished NO bioavailability are
observed in conduit and resistance vessels in hypertensive models
(15, 16). Treatment of spontaneous hypertensive rats with arginase
inhibitor (ABH) has been shown to decrease blood pressure and
improve vascular function (2, 13, 14).
Both ARG1 and ARG2 are expressed constitutively in vascular
tissues (7, 9). However, ARG1 has been shown to modulate vascu-
lar tone in disease conditions such as diabetes (10, 11), ischemia
reperfusion (17), and hypertension (3, 13). However, the relative
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contribution of the ARG isoforms in salt-sensitive hypertension
remains to be determined. To address this issue, we used a genetic
mouse model with either partial deletion of the ARG1 gene or
complete deletion of ARG2 gene. We could not examine com-
plete ARG1 knockout (KO) mice as they do not survive beyond
2 weeks of age due to disruption of the hepatic urea cycle and
hyperammonemia (18). We hypothesized that ARG1 isoform is
involved in increased blood pressure, reduced vasodilator activity,
and increased reactivity to constrictor stimuli in deoxycorticos-
terone acetate (DOCA)-salt hypertensive mice, contributing to
mineralocorticoid hypertension.
MATERIALS AND METHODS
ANIMALS
All procedures were conducted in concordance with the guiding
principles in the care and use of animals, approved by the Georgia
Regents University Committee on the use of Animals in Research
and Education. Mice lacking one copy of ARG1+/− or both copies
of ARG2−/− in a C57BL/6J background at 12 weeks of age were
used in this study. The animals were housed on a 12-h light/dark
cycle and fed a standard chow diet with water or saline ad libitum.
An expanded Section “Materials and Methods” is available in the
online data supplement.
DOCA-SALT HYPERTENSION
Partial ARG1+/−, or complete ARG2−/− KO or control wild
type (WT) mice were unilaterally nephrectomized, and DOCA
(200 mg/mouse) pellets were implanted SC in the scapular region.
DOCA mice received water containing 1.0% NaCl and 0.2% KCl
for 6 weeks. Control mice were unilaterally nephrectomized and
received silastic pellets without DOCA and tap water.
SYSTOLIC BLOOD PRESSURE MEASUREMENTS
Systolic blood pressure (SBP) was measured by tail cuff plethys-
mography (RTBP1001 system, Kent Scientific Corporation,
Conn.) in conscious mice before and under DOCA treatment
once per week thru the 6 weeks of treatment. At the end of the
treatment, mice were euthanized, and aorta and mesenteric artery
(MA) was isolated for further studies (see below).
VASCULAR FUNCTIONAL STUDIES
After euthanasia, thoracic aortas, and second-order branches of
MA were removed and cleaned from fat tissue in ice-cold physi-
ological saline solution. Arterial segments of aorta and MA were
carefully mounted as ring preparations in myograph chambers
(Danish Myo Technology A/S) filled with physiological saline solu-
tion at 37°C (pH 7.4) and continuously bubbled with 5% CO2 and
95% O2. Isometric force was recorded using a powerLab/8SP data
system (AD Instruments, Colorado Springs, CO, USA). Tissues
were adjusted to maintain a passive force of 5 mN for the aortic
and 3 mN for the second-order MA rings. Vessels were equilibrated
for 60 min before experiments.
After equilibration, arterial segments were contracted with
KCl (80 mM) to verify viability of preparations. After washing
out KCl, endothelium integrity was assessed by contracting the
segments with phenylephrine (PE, 1µM; α1-adrenergic receptor
agonist), followed by stimulation with acetylcholine (ACh; 1µM;
an endothelium-dependent vasodilator). Concentration-response
curves to ACh (0.001–10µM) were obtained in aorta or MA after
precontraction with PE (1µM). Then, following construction
of control concentration-response curves to ACh in unilaterally
nephrectomized or DOCA WT mice, tissues were washed sev-
eral times, incubated with an ABH (100µM, 60 min), and then a
second curve was generated. Cumulative concentration-response
curve to sodium nitroprusside (SNP, 0.0001–3µM; a NO donor)
were also performed in aorta and MA precontracted with PE. Addi-
tionally, concentration-response curves to PE (0.001–100µM)
were also performed in aorta or MA.
VASCULAR ARGINASE ACTIVITY ASSAY
Aorta and MA were collected and frozen in liquid nitrogen. Tissues
were pulverized, homogenized in ice-cold lysis buffer (combined
1:4 w/v with 50 mM, Tris-HCl, 100µM, EDTA, and EGTA, pH
7.5) containing protease inhibitor, PMSF, phosphatase inhibitors
cocktail 2 and 3. Homogenates were sonicated and centrifuged at
14,000× g for 20 min at 4°C and supernatants were collected for
enzyme assay. Twenty-five microliters of supernatants in triplicate
were added to 25µL of Tris-HCl 121 (50 mM, pH 7.5) containing
MnCl2 (10 mM) and the mixture were activated by heating for
10 min at 55–60°C. ARG activity was assayed by measuring urea
production from l-arginine as previously described (19).
Additionally, aortas from WT Sham or DOCA mice were treated
with ABH (100µM) for 60 min, then collected and frozen for ARG
activity assay.
WESTERN BLOT ANALYSIS
Protein (20µg) extracted from aortas were separated by elec-
trophoresis on a 10% SDS-polyacrylamide pre-cast gel and trans-
ferred to polyvinylidene difluoride membrane. Non-specific bind-
ing sites were blocked with 5% bovine serum albumin (BSA)
in Tris-buffered saline/Tween for 1 h at 24°C. Membranes were
incubated with primary antibodies (anti-ARG1, BD Transduction
Laboratories, 1:1000; anti-ARG2, Santa Cruz Biotechnology, Inc.,
1:250,Cell Signaling Technology, Inc.) overnight at 4°C. After incu-
bation with secondary antibodies, signals were visualized using
an enhanced chemiluminescence kit (Amersham, Piscataway, NJ,
USA), and quantified by densitometry. Results are normalized to
total actin protein and expressed as arbitrary unit.
CORONARY PERIVASCULAR FIBROSIS
Hearts were embedded in paraffin blocks after fixation in 10%
formalin. Paraffin-embedded sections (5µm thick) were deparaf-
finized with xylene and rehydrated by immersion in a graded series
of ethanol washes. Sections were stained by Picrosirius red fol-
lowing manufacturer’s protocol (Accustain Kit, Sigma-Aldrich).
Collagen deposition around the coronary vessels was detected by
red staining. The area of collagen staining relative to the vessel sur-
face area was quantified using ImageJ (NIH). Perivascular fibrosis
data are expressed as the collagen-to-vessel surface area ratio.
DRUGS AND SOLUTIONS
Physiological saline solution of the following composition was
used: (in mM: NaCl, 118; NaHCO3, 25; glucose, 5.6; KCl, 4.7;
KH2PO4, 1.2; MgSO4·7 H2O, 1.17; and CaCl2·2 H2O, 2.5). ACh,
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SNP, PE, phosphatase inhibitor cocktail 1 and 2 and protease
inhibitor were purchased from Sigma-Aldrich (St. Louis, MO,
USA). The ABH was obtained as a gift from Dr. Daniel Berkowitz.
All of the reagents were of analytic grade. Stock solutions were
prepared in deionized water.
DATA ANALYSIS
Results are presented as mean± SEM, and n represents the num-
ber of animals used in the experiments. Relaxation or contraction
values were calculated relative to the maximal changes from the
contraction produced by PE and KCl, respectively, taken as 100%
in each tissue. Concentration-response curves were fitted using
a non-linear interactive fitting program (Graph Pad Prism 4.0;
GraphPad Software Inc., San Diego, CA, USA), and two pharma-
cological parameters were obtained: the maximal effect generated
by the agonist (or Emax) and the negative logarithm of the concen-
tration of agonist that produces 50% of the maximum response
[−log EC50 (or pEC50)]. ARG activity data is represented as per-
cent change respective to the control (100%). Student’s t -test
or one-way analysis of variance (ANOVA) followed by Bonfer-
roni post hoc test was used to evaluate the results. P < 0.05 was
considered significant.
RESULTS
BODY AND HEART WEIGHT
The body weight of WT and ARG genotype control mice and treat-
ment groups ranged from about 25–27 g and did not differ among
them (Table 1). The heart weight/body weight ratio was elevated
in the DOCA-salt treatment groups of WT and ARG2−/− mice
vs. their respective Sham controls (Figure 1A). However, this ratio
was not different between DOCA and ARG1+/− Sham mice.
SYSTOLIC BLOOD PRESSURE
No differences in SBP measurements were observed among con-
trol WT and arginase KO mice before beginning the experi-
ment at 12 weeks of age; SBP values ranged from 95± 5 to
104± 4 mmHg. After 2 weeks of DOCA treatment, SBP values
for WT, ARG1+/−, and ARG2−/− mice were higher than their
Sham control (Figure 1B). During the third through the sixth week
of DOCA-salt treatment, SBP values in WT and ARG2−/− mice
were steadily increased, whereas SBP in ARG1+/− mice fell back
toward control levels over this period (109± 4 vs. 101± 3 mmHg,
respectively). Of particular note, SBP values for ARG2−/− Sham
mice rose progressively and slightly less than those for ARG2−/−
DOCA mice over the 6-week period, reaching values close to those
Table 1 | Body weight (g) did not differ among WT, ARG1+/−, and ARG2−/− mice in uninephrectomized (WT Sham) or DOCA-salt treated mice.
WT Sham WT DOCA ARG1+/− Sham ARG1+/− DOCA ARG2−/− Sham ARG2−/− DOCA
Body weight (g) 27±2 27±1 26±3 25±2 27±2 26±2
Aorta Emax (%) 98±1 101±3 97±1 93±2 96±2 95±3
Aorta pEC50 8.26±0.07 8.37±0.09 8.14±0.09 8.09±0.07 8.10±0.07 8.17±0.06
MA Emax (%) 100±2 103±2 101±2 99±1 101±1 98±2
MA pEC50 8.40±0.05 8.51±0.06 8.33±0.08 8.26±0.09 8.43±0.05 8.37±0.09
The maximal effect (Emax) and potency (pEC50) values obtained from concentration-response curves to a nitric oxide donor, sodium nitroprusside (SNP, 0.0001–3µM)
in aorta and second-order branches of mesenteric arteries (MA) from WT, ARG1+/−, and ARG2−/− mice in uninephrectomized (WT Sham) or DOCA-salt treated mice.
Data represent the means±SEM of four experiments.
FIGURE 1 | Profile of arginase knockout (KO) mice in
DOCA-salt treatment. Ratio between heart and body weight (A)
and systolic blood pressure (SBP) (B) of WT uninephrectomized
(WT Sham), WT uninephrectomized and DOCA-salt treated (WT
DOCA), partial arginase 1 (ARG1+/−) KO uninephrectomized
(ARG1+/− Sham), ARG1+/− KO and DOCA-salt treated (ARG1+/−
DOCA), arginase 2 (ARG2−/−) uninephrectomized (ARG2−/− Sham),
and ARG2−/− DOCA-salt treated mice. *P <0.05, compared with
its control Sham mice. #P <0.05, comparing upper and lower sets
of SBP levels.
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for WT-DOCA mice. A progressive rise of SBP in non-treated
ARG2−/− mice has been reported (20).
VASCULAR ARGINASE ACTIVITY AND EXPRESSION
Arginase activities were elevated in DOCA WT aorta (1.5-
fold) and MA (2.6-fold) compared to those of Sham WT mice
(Figures 2A,B). Treatment with ABH (100µM) reduced these
elevations in vessels from WT mice. In ARG1+/− mice, DOCA
treatment did not elevate ARG activity in aorta (Figure 2A) or
MA (Figure 2B) vs. those of Sham ARG1+/− mice. In ARG2−/−
DOCA mice, ARG activity was elevated in MA (by 1.55-fold), but
not in aorta, compared to ARG2−/− Sham tissue (Figures 2A,B).
Elevation of ARG activity induced by DOCA treatment in WT ves-
sels was greater than observed in ARG1+/− aorta and ARG2−/−
aorta and MA, but was not different from that in ARG 2−/− DOCA
aorta.
Parallel experiments assessing protein levels of ARG1 showed
significant increases in the DOCA WT aorta by 1.49-fold
(Figure 2C) and in the MA by 1.73-fold (Figure 2D) com-
pared to WT Sham. Protein levels of ARG1 were not increased
in aorta or MA from DOCA ARG1+/− mice, but were elevated
in aorta of DOCA ARG2−/− mice compared to their Sham tissue
(Figures 2C,D). In DOCA WT mice, ARG2 protein was markedly
increased in MA (by 2.15-fold) (Figure 2D). ARG 2 expression
was not detected in WT aorta. Basal ARG1 expression in vessels
from ARG2−/− mice was elevated above that of WT vessels.
Treatment of WT-DOCA aorta with ABH did not prevent ele-
vation of ARG1 protein (not shown). These results indicate that
ARG1 protein levels and activity are elevated by DOCA treatment.
VASOCONTRACTILE RESPONSES TO PHENYLEPHRINE
Concentration-response curves to PE were performed to deter-
mine ARG genotype-related regulation of vascular reactivity to
contractile stimuli. Aortas from WT-DOCA-salt mice displayed a
greater vasoconstriction to PE compared with WT Sham tissues
[maximum efficacy (Emax) of 138± 8 and 114± 6%, respectively].
Contractile responses to PE were lower in the ARG1+/− Sham
(Emax: 93± 6%) compared with those of WT Sham group, but
were elevated in ARG1+/− DOCA mice to the level of WT Sham
mice (Figure 3A). Aortas from ARG2−/− mice exhibited similar
PE-induced contraction to those exhibited by aortas from WT
Sham and DOCA-salt mice (Figure 3B).
FIGURE 2 | Partial deletion of arginase 1 (ARG1+/−) or inhibition of
arginase prevents DOCA-salt-induced increase in vascular arginase
activity/expression. Arginase activity measured in aorta (A) and mesenteric
artery (MA) (B) in WT uninephrectomized (WT Sham), WT uninephrectomized
and DOCA-salt treated (WT DOCA), partial arginase 1 (ARG1+/−) knockout
uninephrectomized (ARG1+/− Sham), ARG1+/− and DOCA-salt treated
(ARG1+/− DOCA), arginase 2 (ARG2−/−) uninephrectomized (ARG2−/− KO
Sham), and ARG2−/− KO DOCA-salt treated mice. Pretreatment with an
inhibitor of arginase (ABH, 100µM) prevented elevation of arginase activity in
aorta and MA in WT-DOCA-salt treated mice (A,B). Measurement of protein
expression of ARG1 and ARG2 in aorta (C) and MA (D) of animals treated
with Sham or DOCA-salt treated WT, ARG1+/−, or ARG2−/− mice. Arginase
activity in WT Sham group was considered as 100%. Data represents
mean±SEM of five to seven experiments. *P <0.05, **P <0.01, compared
with its respective Sham group. #P <0.05, compared with WT-DOCA group.
$P <0.05, compared with WT Sham group.
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FIGURE 3 | Differences in contractile responses induced by
phenylephrine (PE) in DOCA-salt treated arginase knockout (KO) mice.
Concentration-response curves to PE (0.001–10µM) in WT
uninephrectomized (WT Sham), WT uninephrectomized and DOCA-salt
treated (WT DOCA), partial arginase 1 (ARG1+/−) KO uninephrectomized
(ARG1+/− Sham), ARG1+/− and DOCA-salt treated (ARG1+/− DOCA),
arginase 2 (ARG2−/−) uninephrectomized (ARG2−/− Sham) and ARG2−/−
DOCA-salt treated mice in aorta (A,B), and mesenteric artery [MA; (C,D)].
Experimental values were calculated relative to the maximal changes from
the contraction produced by KCl (80 mM), which was taken as 100%. Data
represents mean±SEM of five experiments. *P <0.05, compared with
WT Sham group.
As in aorta, the maximal contractile response to PE was
higher in MA from WT DOCA than in WT Sham MA (Emax:
243± 12 and 195± 9%, respectively). However, no differences
in PE-induced contraction were observed in MA between WT
Sham and ARG1+/− Sham or DOCA mice (Figure 3C). Contrac-
tions induced by PE in MA were similar between WT Sham and
ARG2−/− Sham and between WT-DOCA and ARG2−/− DOCA
groups (Figure 3D).
VASORELAXATION RESPONSES TO ACETYLCHOLINE AND SODIUM
NITROPRUSSIDE
Endothelial dysfunction is a well-established feature of the DOCA-
salt hypertensive animal model (21, 22). To determine the effect of
ARG genotype on vascular function, we compared vasorelaxation
responses to ACh (0.001–10µM) in aorta from WT, ARG1+/−,
or ARG2−/− mice after 6 weeks of DOCA-salt with those in
Sham mice. Similar aortic vasorelaxation responses to ACh were
observed between WT and ARG1+/− Sham mice (Emax: 68± 2%;
pEC50: 7.42± 0.09 and Emax: 70± 5%; pEC50: 7.50± 0.07 for
WT and ARG1+/− mice, respectively, Figure 4A). DOCA-salt
markedly reduced maximal responses to ACh in WT aorta (Emax:
55± 4%) compared to their Sham control (Emax: 68± 2%),
whereas vasorelaxation responses to ACh in ARG1+/− Sham and
DOCA-salt vessels were not different (Emax: 70± 5 and 65± 2%,
respectively) (Figure 4A). Aorta from ARG2−/− Sham mice
showed similar Emax values (63± 4%) but displayed impaired
sensitivity (pEC50) to ACh compared with those of WT Sham
mice (pEC50: 6.94± 0.09 and 7.42± 0.09 for vessels of ARG2−/−
and WT Sham, respectively). Aortas from ARG2−/− DOCA mice
exhibited an impaired ACh-induced maximum vasorelaxation vs.
their sham control (pEC50: 6.54± 0.07; Emax: 52± 5%) which was
not different from that of WT-DOCA aorta (Figure 4B).
The MA of WT-DOCA mice displayed impaired vasorelaxation
to ACh (Emax: 78± 3%) compared to WT Sham (Emax: 95± 3%),
but this impairment was absent in MA of ARG1+/−mice Sham and
DOCA mice (Emax 93± 2 and 92± 2%, respectively) (Figure 4C).
The MA from the ARG2−/− DOCA mice exhibited impairment of
endothelial cell (EC)-dependent vasorelaxation similar to that of
MA from WT-DOCA mice (Figure 4D). As in aorta, there tends
to be impaired relaxation to ACh in ARG2−/− Sham MA.
Acute treatment with ABH (100µM) significantly enhanced
the Emax to ACh in aortas (Figure 5A) and MA (Figure 5C)
from WT-DOCA mice (from 60± 5 to 79± 3% and from 76± 3
to 88± 2%, for aorta and MA, respectively). However, ABH did
not alter the vasorelaxation to ACh in the WT Sham groups
(Figures 5B,D).
Endothelium-independent relaxations in aorta or MA induced
by the NO donor, SNP were not different between uninephrec-
tomized (WT Sham) and DOCA-salt treatment in WT, ARG1+/−,
and ARG2−/− mice, respectively (Table 1).
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FIGURE 4 | Partial deletion of arginase 1 (ARG1+/−) prevents
DOCA-salt-induced endothelial dysfunction in aorta and mesenteric
artery (MA). Concentration-response curves to acetylcholine (ACh,
0.001–10µM) in aorta (A,B) and MA (C,D) from WT, ARG1+/−, or ARG2−/−
mice in uninephrectomized (WT Sham) or DOCA-salt treated mice. Data
were calculated relative to the maximal changes from the contraction
produced by phenylephrine (PE, 1µM), which was taken as 100%. Data
are means±SEM of six to eight experiments. *P <0.05, indicates
differences in pEC50 values of the dose-response curves. #P <0.05,
compared with WT Sham group.
CORONARY PERIVASCULAR FIBROSIS
Fibrosis was assessed as the amount of tissue collagen around
the coronary arteries. WT-DOCA mice exhibited enhanced coro-
nary perivascular fibrosis, as evident by the increased picrosir-
ius red stain of collagen around the coronary vessel com-
pared with control WT mice (Figure 6A). Importantly, col-
lagen staining was not increased in ARG1+/− DOCA mice
compared to Sham control. Additionally, the ratio of coro-
nary perivascular fibrosis to total vessel surface area increased
markedly for WT-DOCA (2.1-fold) and significantly, but to a
lesser extent (1.22-fold) in the ARG2−/− DOCA vs. Sham mice,
while no significant alteration in this ratio was observed in
DOCA ARG1+/− or Sham mice (Figure 6B). Our data indicate
that increase ARG activity is associated with increased collagen
production.
DISCUSSION
The major findings of this study are the contributions of arginase
(ARG1 and ARG2) to elevated blood pressure, impaired EC-
dependent vasorelaxation, increased vasoreactivity to constrictor
stimuli, and enhancement of coronary perivascular fibrosis in a
model of DOCA-salt hypertension. Several important observa-
tions have been made in our study. First, we show that SBP levels
in ARG1+/− DOCA do not rise as they do in WT-DOCA mice.
The rise in SBP in WT-DOCA mice is similar to that reported by
others (23, 24). In contrast, both ARG2−/− Sham and DOCA mice
exhibited progressive elevation in SBP, with a slightly greater rise
in DOCA mice. A progressive hypertension has been reported for
ARG2 KO mice (20). Second, vascular ARG activity is increased
in aorta and second-order resistance MA from WT-DOCA-salt
mice. Reduction or lack of the ARG1 or ARG2 genes prevented
the DOCA-induced increase in aortic ARG activity, but only in
ARG1+/− aorta was activity lower than in WT aorta. Third, in
WT-DOCA mice, protein levels of ARG1 are increased in aorta
and both ARG1 and ARG2 are up-regulated in MA. Fourth,
DOCA-induced impairment of endothelium-dependent vasore-
laxation in aorta and MA is prevented in ARG1+/− DOCA mice,
and partially so in ARG2−/− compared with its Sham control.
These findings indicate that both ARG isoforms contribute to
DOCA-induced vascular dysfunction, to varying degrees. Fifth,
augmented contractile responses to the α-1-adrenergic agonist PE
occur in aorta and MA from DOCA treated WT, ARG1+/−, and
ARG2−/−mice. Sixth, coronary perivascular fibrosis in DOCA-salt
mice is prevented or reduced by deletion of ARG1+/− or ARG2−/−,
respectively.
Our findings indicate that enhancement of vascular ARG activ-
ity induced by ARG1 isoform has a key role in salt-induced
hypertension. Salt sensitivity is associated with almost half of
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FIGURE 5 | Inhibition of arginase ameliorates DOCA-salt-induced
endothelial dysfunction. Treatment with an inhibitor of arginase (ABH,
100µM; 60 min) prevented vascular endothelial dysfunction in
DOCA-salt treated mice in aorta (A) and mesenteric artery [MA; (C)].
WT Sham vessels exposed to ABH showed no change in the
ACh-induced vasorelaxation in aorta (B) and MA (D). Data were
calculated relative to the maximal changes in contraction produced by
phenylephrine (PE, 1µM), which was taken as 100%. Data are
means±SEM of four experiments. *P <0.05, compared with
WT-DOCA+ABH group.
the cases of human hypertension (25). DOCA-salt hypertension
is volume-dependent and is accompanied by low plasma renin-
angiotensin system activity. The combination of DOCA-salt and
unilateral nephrectomy result in hypertension and cardiac and
renal hypertrophy. Increased vascular ARG has been linked in
animal model for hypertension (3, 15, 16). The two isoforms
of ARG have been shown to have different intracellular and tis-
sue distributions (4, 7, 26). Depending on the disease state and
tissue, ARG1, ARG2, or both may be elevated and exert promi-
nent actions. Earlier studies have demonstrated up-regulation of
both ARG isoforms in gracilis muscle arterioles and in aorta from
Dahl-salt-sensitive (16) and spontaneously hypertensive rat (27).
However, only ARG1 is reported to be increased in aorta from
DOCA-salt rats (15), coronary arteries from pigs with aortic coarc-
tation (13) and MA from genetic hypertensive rats (2). Our data
show that absence of one copy of ARG1 gene prevents rises in
SBP, indicating its involvement in DOCA hypertension. The rise
in blood pressure in ARG2−/− mice complicates assessment of
ARG2’s role in DOCA hypertension. Absence of both ARG2 gene
copies partially reduced but did not prevent elevation of SBP in
DOCA-salt mice.
Phenylephrine-induced contractions in aorta from ARG1+/−,
but not ARG2−/−, Sham mice were less than WT Sham mice,
suggesting that activity of ARG1, but not ARG2, decreases aortic
endothelial NO release in response to PE. A reduced contractile
response was not observed in MA of ARG1+/− Sham mice, possi-
bly due to activity of ARG2. Importantly, contractile responses in
aorta of all the mouse genotypes were enhanced by DOCA treat-
ment, indicating that the DOCA-induced enhanced contraction
did not involve either ARG isoform.
Deoxycorticosterone acetate-induced vascular endothelial dys-
function was largely absent in aorta and MA of ARG1+/− mice.
DOCA-induced dysfunction in ARG2−/− was less pronounced vs.
its sham controls, as the ARG2−/− sham displayed a degree of
impairment vs. WT sham. Thus, this isoform may contribute to
vascular endothelial dysfunction. An important question is, how
does lack of ARG2 cause this dysfunction.
Arginase can compete with NOS for the common sub-
strate l-arginine in the vasculature. Increased vascular ARG
activity/expression and decreased NO production have been
observed in hypertension and diabetes (3, 10, 13, 19). The
products of ARG action on l-arginine are urea and ornithine
(28). Elevated ornithine levels from excessive ARG activity also
could contribute to pathological vascular fibrosis and thick-
ening by increasing the formation of polyamines and proline
from ornithine. Polyamines and proline promote cell growth and
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FIGURE 6 | Partial deletion of one copy of arginase 1 (ARG1) prevents
coronary perivascular fibrosis in DOCA-salt treated mice. Assessment
of coronary perivascular fibrosis from WT, ARG1+/−, and ARG2−/− mice in
uninephrectomized (WT Sham) or DOCA-salt treated mice using
picrosirius red staining (red color for collagen). (A) Shows a representative
photograph of left ventricular paraffin-embedded tissue sections.
Quantitative ratio of the perivascular collagen area to the vessel wall
surface area is provided in (B). Data are means±SEM of three to four
experiments. **P <0.01, *P <0.05, compared with its Sham group.
#P <0.05, compared with WT-DOCA group.
collagen formation, respectively (29, 30). Our findings demon-
strate that DOCA-salt induces cardiac hypertrophy and increases
perivascular collagen deposition in WT mice, and that these effects
are absent in ARG1+/− mice. Lack of ARG2 also reduces DOCA-
induced perivascular fibrosis. Long term treatment of SHR with an
ABH has been shown to reduce blood pressure and cardiac fibro-
sis (2). Our data suggest that increased ARG1 mediates cardiac
hypertrophy and perivascular fibrosis through increased synthe-
sis of polyamines and proline. Elevated blood pressure/vascular
resistance also contribute to cardiac hypertrophy. Earlier stud-
ies have demonstrated that hypertension, diabetes, atherosclerosis,
and aging are associated with elevated vascular stiffness/decreased
arterial compliance, which is recognized as an important and
independent cardiovascular risk factor (31). Further studies are
needed to determine whether reduction of ARG1 gene expres-
sion diminishes vascular stiffness via decreased levels of ornithine,
polyamines, and proline.
The pathogenesis of DOCA-salt hypertension in conduit arter-
ies is reported to involve increased reactive oxygen species (ROS)
production (32). Superoxide and peroxynitrite contribute to
increased vascular ARG activity, decreased l-arginine availability
to eNOS and its uncoupling, reduced NO production, and even
greater levels of these ROS (33, 34). Both peroxynitrite and hydro-
gen peroxide increase endothelial ARG expression/activity and
inhibition of NADPH oxidase blocks this action of hydrogen
peroxide (34). NOS uncoupling also would limit the produc-
tion of N G-hydroxyl-l-arginine (NOHA), an intermediate prod-
uct in the generation of NO and a potent inhibitor of ARG.
Inhibition of NADPH oxidase by apocynin has been reported
to prevent elevation of ARG activity and largely prevent a
lipopolysaccharide (LPS)-induced increase in ARG1 mRNA in
rat alveolar macrophages (35). Additionally, exposure of cul-
tured rat retinal cells to LPS also strongly induces expres-
sion of ARG1, which is markedly reduced by apocynin co-
treatment (36). It is probable that ROS are involved in the
elevation of ARG1 activity and expression observed in our
study.
In our model, DOCA treatment progressively increased SBP
in WT and ARG2−/− mice. Moreover, SBP also rose in the
Sham ARG2−/− mice verses Sham WT mice. Huynh et al. (20)
Frontiers in Immunology | Inflammation July 2013 | Volume 4 | Article 219 | 8
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Toque et al. Involvement of arginase in hypertension
have previously reported a progressive rise in blood pressure in
ARG2−/− KO mice along with increased plasma levels of the
norepinephrine (NE) precursor (dihydroxyphenylalanine) and its
metabolite (dihydroxyphenylglycol). Their data suggest that sym-
pathetic nervous activity is increased in the cardiovascular system
and responsible for elevated blood pressure in these ARG2−/−
mice. Further study is needed to more clearly define how ARG2
regulates blood pressure.
In summary, our results showed that ARG is involved in
the pathogenesis of hypertension. Using a genetic approach,
we conclude that both ARG isoforms contribute to vascular
endothelial dysfunction in DOCA-salt hypertension.
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